Sweden's Q-Linea Q4 net sales rise

Q Linea AB

04/02/2026 06:38

Overview

Swedish infection diagnostics firm's Q4 net sales rose significantly yr/yr

Company reported a smaller net loss compared to last year

Company completed rights issue, raising approximately SEK 312 mln

Outlook

Company plans to launch version 2 menu in U.S. by Q2 2026

Q-Linea expects further CoGS reductions through process optimisation in 2026

Company aims for breakeven by 2027 through cost control and revenue growth

Result Drivers

U.S. MARKET EXPANSION - Q-Linea signed its first commercial contracts in the U.S., marking a significant step in its market presence

COST REDUCTION - Implemented a cost-reduction program, reducing operating expenses by 10%

RIGHTS ISSUE - Completed rights issue raised approximately SEK 312 mln, providing financial support for growth plans

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 2.90 mln
Q4 Adjusted EPS
-SEK 3.73
Q4 Net Income
-SEK 46.90 mln
Q4 Adjusted Free Cash Flow
-SEK 39.90 mln
Q4 EBIT
-SEK 44.10 mln


Analyst Coverage

Wall Street's median 12-month price target for Q linea AB is SEK55.00, about 113% above its February 3 closing price of SEK25.83

Press Release: ID:nMFN3ng9C5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)